Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | -6.40% | -1.68% | -28.33% |
Business Summary
Number of employees: 31
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia, Switzerland and Spain
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Comptroller/Controller/Auditor | 35 | 22-06-30 | |
Corporate Officer/Principal | - | - | |
Manolo Bellotto
PRN | Corporate Officer/Principal | 53 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 20-12-31 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 20-12-31 |
Director/Board Member | 68 | 20-12-31 | |
Jeffrey Riley
BRD | Director/Board Member | 61 | 19-04-30 |
Khalid Islam
FOU | Founder | 67 | 16-12-31 |
Claude Nicaise
BRD | Director/Board Member | 71 | 20-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,051,979 | 16,832,597 ( 93.25 %) | 0 | 93.25 % |
Company contact information
Gain Therapeutics, Inc.
4800 Montgomery Lane Suite 220
20814, Bethesda
+
http://www.gaintherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.33% | 45.13M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- GANX Stock
- Company Gain Therapeutics, Inc.